| 000 | 01079 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513215124.0 | ||
| 264 | 0 | _c20000801 | |
| 008 | 200008s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(00)01029-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLane, D M | |
| 245 | 0 | 0 |
_aWhy not phenytoin. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cJul 2000 |
||
| 300 |
_a125-6 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAnticonvulsants _xtherapeutic use |
| 650 | 0 | 4 |
_aCholesterol, HDL _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypercholesterolemia _xblood |
| 650 | 0 | 4 |
_aMyocardial Ischemia _xetiology |
| 650 | 0 | 4 |
_aPhenytoin _xtherapeutic use |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriglycerides _xblood |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 86 _gno. 1 _gp. 125-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(00)01029-8 _zAvailable from publisher's website |
| 999 |
_c10877926 _d10877926 |
||